-+ 0.00%
-+ 0.00%
-+ 0.00%

Aclaris Therapeutics Q3 net loss widens 27% to $18.51 million

PUBT·11/05/2026 12:04:14
Aclaris Therapeutics Q3 net loss widens 27% to $18.51 million
  • Aclaris Therapeutics’ third-quarter 2026 net loss widened 27% year over year to $18.51 million.
  • Revenue dropped 55% to $1.48 million, primarily due to a Sun Pharma licensing milestone achieved in the prior-year quarter.
  • October’s offering raised $50 million in gross proceeds; including net proceeds, cash runway is expected through the first half of 2029.
  • Bosakitug Phase 2 atopic dermatitis results and modzatinib Phase 2b lichen planus trial initiation are expected in fourth-quarter 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050659PRIMZONEFULLFEED9870550) on November 05, 2026, and is solely responsible for the information contained therein.